کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2151456 | 1089994 | 2012 | 15 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
PLK1PARPTGFαGEMshRNAX-Gal5-bromo-4-chloro-3-indolyl-β-d-galactopyranosideFACSPBSAdV3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide - 3- (4،5-dimethylthiazol-2-yl) -2،5-difenyltetrazolium bromideHCC - HCCMTT - MTTRNA interference - RNA تداخل کنندهRNAi - RNA سرکوبگر،RNA مداخلهگر، RNA خاموش کنندهshort hairpin RNA - RNA موی سر کوتاهAdenovirus - آدنوویروسMRI - امآرآی یا تصویرسازی تشدید مغناطیسیstandard deviation - انحراف معیارtransforming growth factor-α - تبدیل فاکتور رشد αMagnetic resonance imaging - تصویربرداری رزونانس مغناطیسیfluorescence-activated cell sorting - دسته بندی سلول های فعال فلورسنسCMV - سیتومگالوویروسPhosphate-buffered saline - محلول نمک فسفات با خاصیت بافریgenetically engineered mouse - موش های مهندسی ژنتیکیplaque-forming units - واحدهای پلاک سازیpfu - پفوPolo-like kinase 1 - پلی کیناز 1Poly(ADP-ribose) polymerase - پلیمر (ADP-ribose) پلیمرازHepatocellular carcinoma - کارسینوم هپاتوسلولار(کارسینوم سلولهای استخوانی)
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels](/preview/png/2151456.png)
چکیده انگلیسی
Highly promising preclinical data obtained in cultured cells and in nude mice bearing xenografts contrast with the rather modest clinical efficacy of Polo-like kinase 1 (Plk1) inhibitors. In the present study, we investigated if Plk1 might be a suitable target in hepatocellular carcinoma (HCC) and if a genetically engineered mouse tumor model that well reflects the tumor cell and micro-environmental features of naturally occurring cancers might be suitable to study anti-Plk1 therapy. Analysis of Plk1 expression in human HCC samples confirmed that HCC express much higher Plk1 levels than the adjacent normal liver tissue. Inhibition of Plk1 by an adenovirus encoding for a short hairpin RNA against Plk1 or by the small-molecule inhibitor BI 2536 reduced the viability of HCC cell lines and inhibited HCC xenograft progression in nude mice. Treatment of transforming growth factor (TGF) α/c-myc bitransgenic mice with BI 2536 during hepatocarcinogenesis reduced the number of dysplastic foci and of Ki-67-positive cells within the foci, indicating diminished tumorigenesis. In contrast, BI 2536 had no significant effect on HCC progression in the transgenic mouse HCC model as revealed by magnetic resonance imaging. Measurement of BI 2536 by mass spectrometry revealed considerably lower BI 2536 levels in HCC compared with the adjacent normal liver tissue. In conclusion, low intratumoral levels are a novel mechanism of resistance to the Plk1 inhibitor BI 2536. Plk1 inhibitors achieving sufficient intratumoral levels are highly promising in HCC treatment.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Neoplasia - Volume 14, Issue 5, May 2012, Pages 410-419, IN6-IN10
Journal: Neoplasia - Volume 14, Issue 5, May 2012, Pages 410-419, IN6-IN10
نویسندگان
Jörg Haupenthal, Verena Bihrer, Huedayi Korkusuz, Otto Kollmar, Christian Schmithals, Susanne Kriener, Knut Engels, Thomas Pleli, Alexander Benz, Marta Canamero, Thomas Longerich, Bernd Kronenberger, Swantje Richter, Oliver Waidmann, Thomas J. Vogl,